Cited by 54Retinoids in leukemia and cellular processesAcute Myeloid Leukemia ResearchPeroxisome Proliferator-Activated Receptors

Molecular pathogenesis of acute promyelocytic leukaemia and APL variants

Sirulnik, Andres, Melnick, Ari, Zelent, Arthur, Licht, Jonathan D·2003·Best Practice & Research Clinical Haematology

Abstract

It has been 12 years since the simultaneous discovery of the unique sensitivity of acute promyelocytic leukaemia (APL) to differentiation therapy with all-trans retinoic acid (ATRA) and the discovery that the retinoic acid receptor alpha (RARalpha) gene was rearranged in APL. Nearly 98% of cases of APL are associated with t(15;17) chromosomal translocation and fusion of the PML gene to that encoding RARalpha to yield an abnormal receptor with the capability of de-regulating gene expression in the haematopoietic cell, causing differentiation block and eventually the development of leukaemia. Since this original discovery, four other translocations were described in APL. In each of these the RARalpha gene is fused to different partner genes, all yielding aberrant nuclear receptors. These fusion proteins share in common the ability to repress rather than activate retinoic acid targets, one so strongly that the result is an ATRA-resistant form of the disease. In addition each of the partner proteins is important for normal cell growth and development. In this chapter we explore the biology of the RARalpha, the fusion proteins created in APL and the normal forms of the partner proteins. Through continued study of this disease it is hoped that novel treatments, potentially more applicable to other forms of leukaemia, may arise.

Integrity signals

Registry

Crossref · 10.1016/s1521-6926(03)00062-8

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The t(15;17) translocation, the cytogenetic marker for APL, involves the RARA gene on chromosome 17q21.

    “the t(15;17) translocation, the cytogenetic marker for APL involves the RARA gene on chromosome 17q21”

    From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Sirulnik et al, 2003

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sirulnik, A., Melnick, A., Zelent, A., & Licht, J. D.
Affiliations
  • Mount Sinai Hospital (US)
  • Albert Einstein College of Medicine (US)
  • Institute of Cancer Research (GB)
Corresponding author
Licht, Jonathan D
Venue
Best Practice & Research Clinical Haematology
Publisher
Elsevier BV
Published
2003-09
Volume
16
Issue
3
Pages
387-408
ISSN
1521-6926 (ISSN-L)
OpenAlex
W2104222293
Cited by
54
References
174
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 3 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 2
FWCI
0.16
Type
journal article
Language
en
Open access
closed
Locations
  • Best Practice & Research Clinical Haematology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
acute promyelocytic leukemia, retinoic acid receptor alpha, PML-RARA fusion, all-trans retinoic acid, ATRA resistance, differentiation block, molecular pathogenesis
MeSH terms
Retinoic Acid Receptor alpha, Humans, Translocation, Genetic, Gene Rearrangement, Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Receptors, Retinoic Acid, Genetic Heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review